MHLW Designates Biogen Idec’s MS Drug Natalizumab Orphan Drug
This article was originally published in PharmAsia News
Executive Summary
The first session of Japan's Ministry of Health, Labor and Welfare's drug review board designated Biogen Idec's natalizumab an orphan drug April 25. Marketed under Tysabri, natalizumab is approved in the United States for treating relapsing forms of multiple sclerosis, and in the European Union for relapsing-remitting forms of MS. Biogen Idec Japan, the American company's Japanese subsidiary plans to start clinical trials in Japan soon. (Click here for more - Japanese language)